CUE
Cue Biopharma
NASDAQ: CUE · HEALTHCARE · BIOTECHNOLOGY
$14.74
+13.38% today
Updated 2026-04-30
Market cap
$57.60M
P/E ratio
—
P/S ratio
2.10x
EPS (TTM)
$-8.40
Dividend yield
—
52W range
$5 – $31
Volume
11.4M
Cue Biopharma (CUE) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+55.8%
Last 4 quarters
Revenue YoY growth
+1292.3%
Most recent quarter
EPS YoY growth
+107.8%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.2%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.6%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-24 | $0.01 | +111.1% | $0.27 | $0.26 | -0.8% |
| 2025-11-13 | $-0.07 | +22.2% | $0.67 | $0.63 | -5.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.09 | $0.01 | +111.1% | $21.94M | +1292.3% |
| 2025-09-30 | $-0.09 | $-0.07 | +22.2% | $2.15M | -35.6% |
| 2025-06-30 | $-0.14 | $-0.09 | +35.7% | $2.95M | +11.1% |
| 2025-03-31 | $-0.28 | $-0.13 | +54.3% | $421000.00 | -75.5% |
| 2024-12-31 | $-0.15 | $-0.13 | +11.7% | $1.58M | -13.5% |
| 2024-09-30 | $-0.19 | $-0.17 | +10.1% | $3.34M | +58.9% |
| 2024-06-30 | $-0.28 | $-0.20 | +28.6% | $2.66M | +92.3% |
| 2024-03-31 | $-0.28 | $-0.25 | +10.7% | $1.72M | +818.2% |
| 2023-12-31 | $-0.28 | $-0.29 | -3.6% | $1.82M | — |
| 2023-09-30 | $-0.34 | $-0.24 | +29.4% | $2.10M | — |
| 2023-06-30 | $-0.30 | $-0.29 | +3.3% | $1.38M | — |
| 2023-03-31 | $-0.29 | $-0.29 | +0.0% | $187000.00 | — |
Frequently asked questions
Has Cue Biopharma beaten earnings estimates?
Cue Biopharma has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +55.8% over the last 4 quarters.
How does CUE stock react to earnings?
CUE stock has moved an average of -3.2% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.
What is Cue Biopharma's revenue growth rate?
Cue Biopharma reported year-over-year revenue growth of +1292.3% in its most recent quarter, with EPS growing +107.8% year-over-year.